Loading
A phase 2 trial of PF-08634404 in small-cell lung cancer, run by Pfizer, now recruiting.
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07476287 by Pfizer, with 40 participants planned, started 2026-07-02 and due to reach its primary completion in 2028-03-19. Interventions recorded: PF-08634404, Chemotherapy. Conditions listed: Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PF-08634404, Pfizer (incl. Seagen), Small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen), Small-cell lung cancer.
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/